In last trading session, Stoke Therapeutics Inc (NASDAQ:STOK) saw 1.05 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $9.30 trading at -$0.41 or -4.22% at ring of the bell on the day assigns it a market valuation of $492.59M. That closing price of STOK’s stock is at a discount of -89.03% from its 52-week high price of $17.58 and is indicating a premium of 44.73% from its 52-week low price of $5.14.

For Stoke Therapeutics Inc (STOK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.53 in the current quarter.

Stoke Therapeutics Inc (NASDAQ:STOK) trade information

Upright in the red during last session for losing -4.22%, in the last five days STOK remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $9.30 price level, adding 16.29% to its value on the day. Stoke Therapeutics Inc’s shares saw a change of -15.68% in year-to-date performance and have moved -9.88% in past 5-day. Stoke Therapeutics Inc (NASDAQ:STOK) showed a performance of -0.64% in past 30-days.

Wall Street analysts have assigned a consensus price target of 26.5 to the stock, which implies a rise of 64.91% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -93.55% in reaching the projected high whereas dropping to the targeted low would mean a loss of -93.55% for stock’s current value.

Stoke Therapeutics Inc (STOK) estimates and forecasts

This year revenue growth is estimated to rise 104.06% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.2M for the same. And 4 analysts are in estimates of company making revenue of 2.83M in the next quarter. Company posted 2.8M and 4.22M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -44.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 15.21% while estimates for its earnings growth in next 5 years are of -3.38%.

Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders

SKORPIOS TRUST is the top institutional holder at STOK for having 10.84 million shares of worth $146.5 million. And as of 2024-06-30, it was holding 23.4474 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 5.41 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.6963 of outstanding shares, having a total worth of $73.08 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.61 shares of worth $14.95 million or 3.04% of the total outstanding shares. The later fund manager was in possession of 988.96 shares on Nov 30, 2024 , making its stake of worth around $9.2 million in the company or a holder of 1.87% of company’s stock.